hERG screening alone may be insufficient to flag potential cardiac liability. Conversely, abandoning promising compounds based on hERG blockade alone may result in failing potentially safe clinical drugs.
Creative Bioarray's [[ https://acroscell.creative-bioarray.com/cipa-cardiac-channel-assays.html | CiPA service ]] provides you with a robust cost-effective approach to determine cardiac risk, earlier in your program and with turnaround times that support your lead discovery and optimization pipeline.